NeoGenomics, Inc. (NASDAQ:NEO) Q4 2020 Earnings Conference Call February 24, 2021 8:30 AM ET Company Participants Doug VanOort - Chairman, CEO Kathryn McKenzie - CFO Rob Shovlin - President, Clinical Division Bill Bonello - President, Informatics Division Doug Brown - Chief Strategy, CDO Charlie Eidson - Manager, IR Larry Weiss - CMO, Director of R&D George Cardoza - President, Pharma Services Division Lynn Tetrault - LID of Board of Directors Conference Call Participants David Westenberg - Guggenheim Secur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorpor ...

NeoGenomics, Inc. (NASDAQ:NEO) Q3 2020 Results Earnings Conference Call October 27, 2020 8:30 AM ET Company Participants Doug VanOort - Chairman and CEO Kathryn McKenzie - Chief Financial Officer Rob Shovlin - President, Clinical Services Division George Cardoza - President, Pharma Services Division Bill Bonello - President, Informatics Division Doug Brown - Chief Strategy and Corporate Development Officer Charlie Eidson - Manager, Investor Relations Conference Call Participants Alex Nowak - Craig-Hallum Ca ...

Company Overview - NeoGenomics is a leading oncology testing company, serving over 2,600 hospitals and cancer centers[8] - The company performs approximately 1,000,000 tests per year, serving around 500,000 patients annually[8] - Pharma Services backlog is approximately $173 million[9] Market and Growth - The oncology test market is estimated to grow at a rate of 6% to 8%[10] - The number of U S cancer survivors is projected to reach 26 1 million by 2040[13] - The company looks to grow twice the market rate, driven by company-specific growth drivers[21, 22] Financial Performance (Q2 2020) - Pharma Services new business reached $40 million[35] - Pharma Services backlog increased by 63% year-over-year[35] - Clinical Services revenue for Q2 2020 was $73 884 million, a decrease of 17 0% compared to Q2 2019 ($88 982 million)[66] - Pharma Services revenue for Q2 2020 was $13 093 million, an increase of 2 8% compared to Q2 2019 ($12 731 million)[66]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exac ...

Financial Data and Key Metrics Changes - Consolidated revenue declined 14% year-over-year to $87 million due to the impact of the COVID-19 pandemic [27] - Adjusted EBITDA was negative $7.2 million reflecting significant volume declines and challenges related to COVID-19 [34] - Gross margin declined year-over-year to 32.2% as a result of volume and cost impacts from the pandemic [33] Business Line Data and Key Metrics Changes - Clinical division test volume excluding COVID-19 testing declined 18% year-over-year, with April representing the lowest point [28] - Pharma services revenue increased 3% year-over-year to $13 million, with net bookings of signed contracts at an all-time high of $40 million during the quarter [32] - Revenue per test in the clinical division was $351, down 1% year-over-year and down sequentially from $371 [30] Market Data and Key Metrics Changes - The COVID impact on testing volume was most severe in April, with volume down nearly 30% year-over-year [24] - Volume began to recover in May and June, with June 2020 volume essentially in line with June 2019 volume, though still about 15% below pre-COVID expectations [25] - The backlog of signed contracts in pharma services increased 63% year-over-year to $173 million [32] Company Strategy and Development Direction - The company retained all employees during the crisis and built a COVID testing lab, currently capable of performing over 10,000 tests per day [9][12] - A strategic collaboration and $25 million minority investment in Inivata was formed to enhance liquid biopsy testing capabilities [15] - Continued investment in informatics and pharma services, with a focus on international expansion and strengthening testing capabilities [20][80] Management's Comments on Operating Environment and Future Outlook - Management expects a rapid and strong recovery in financial results in the third quarter, with organic revenue growth in excess of 20% anticipated [23] - There is uncertainty about the volume and duration of demand for COVID-19 testing, but it is expected to result in incremental revenue and profit [12] - Management expressed confidence in the company's competitive position and long-term growth prospects, stating that strategic decisions made during the pandemic have positioned the company for recovery [26][45] Other Important Information - The company successfully completed an offering of common stock and convertible securities resulting in net proceeds of $322 million, enhancing financial flexibility [14] - Days sales outstanding increased six days sequentially to 92 days due to revenue distribution being heavily weighted towards June [37] - The construction of a new state-of-the-art laboratory and global headquarters in Fort Myers, Florida, is on track for opening in the fall of 2021 [35] Q&A Session Summary Question: Details on rolling out newer liquid biopsy tests - The company is providing extensive education for clients regarding the new liquid biopsy tests, as many clients have limited experience with liquid-based tests [50] Question: Volume recovery compared to pre-COVID levels - Management believes there is pent-up demand, but many cancer patients have delayed visits due to COVID-19 concerns [52] Question: Contribution of COVID testing to organic growth guidance - The company expects the 20% revenue growth to be driven by modest growth in core oncology and COVID testing, but there is uncertainty in the numbers [57][58] Question: Margin expectations from COVID testing - The margin profile for COVID testing is lower than normal clinical testing margins, and overall margins are expected to remain under pressure until volumes stabilize [60][107] Question: Competitive environment in pharma services - The company has a strong service focus and global capabilities, which differentiate it from smaller competitors [92] Question: Impact of COVID on clinical trial activities - COVID has caused delays in clinical trials, but there are signs of recovery with new trials starting in July [95] Question: Future of oncology testing outsourcing - Management does not foresee a fundamental shift towards more in-house oncology testing by hospitals, as they continue to refer work to the company [110]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or For the transition period from _________ to __________ Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 12701 Commonwealth Dr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organizat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 Indicate by check mark whether the registrant ...